data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Nabriva Therapeutics
(NASDAQ:NBRV)
0.204
0.0017[0.84%]
At close: Jun 24
0.204
00
After Hours: 4:51PM EDT
Day High/Low0.2 - 0.21
52 Week High/Low0.18 - 1.41
Open / Close0.21 / 0.2
Float / Outstanding62.9M / 63.2M
Vol / Avg.314K / 539.8K
Mkt Cap12.9M
P/E-
50d Avg. Price0.24
Div / Yield-
Payout Ratio-
EPS-0.2
Total Float62.9M

Nabriva Therapeutics (NASDAQ:NBRV), Quotes and News Summary

Nabriva Therapeutics (NASDAQ: NBRV)

Day High/Low0.2 - 0.21
52 Week High/Low0.18 - 1.41
Open / Close0.21 / 0.2
Float / Outstanding62.9M / 63.2M
Vol / Avg.314K / 539.8K
Mkt Cap12.9M
P/E-
50d Avg. Price0.24
Div / Yield-
Payout Ratio-
EPS-0.2
Total Float62.9M
Benzinga - May 5, 2022, 4:52PM
Benzinga - May 5, 2022, 7:19AM
Benzinga - Apr 11, 2022, 4:05PM
Benzinga - Mar 30, 2022, 9:52AM
Benzinga - Mar 29, 2022, 4:25PM
Benzinga - Mar 29, 2022, 4:04PM
Benzinga - Feb 7, 2022, 7:52AM
Benzinga - Jan 10, 2022, 7:30AM
Benzinga - Nov 29, 2021, 9:02AM
Benzinga - Nov 11, 2021, 7:04AM
Benzinga - Nov 9, 2021, 4:36PM
Benzinga - Oct 4, 2021, 4:08PM
Benzinga - Oct 1, 2021, 7:02AM
Benzinga - Sep 16, 2021, 9:03AM
load more
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.190-0.200 -0.0100
REV9.570M8.020M-1.550M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Nabriva Therapeutics Questions & Answers

Q
How do I buy Nabriva Therapeutics (NBRV) stock?
A

You can purchase shares of Nabriva Therapeutics (NASDAQ: NBRV) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Nabriva Therapeutics's (NBRV) competitors?
A

There are no as such competitors for Nabriva Therapeutics.

Q
What is the target price for Nabriva Therapeutics (NBRV) stock?
A

The latest price target for Nabriva Therapeutics (NASDAQ: NBRV) was reported by Northland Capital Markets on Wednesday, March 30, 2022. The analyst firm set a price target for 2.00 expecting NBRV to rise to within 12 months (a possible 880.39% upside). 1 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Nabriva Therapeutics (NBRV)?
A

The stock price for Nabriva Therapeutics (NASDAQ: NBRV) is $0.204 last updated June 24, 2022, 8:00 PM UTC.

Q
Does Nabriva Therapeutics (NBRV) pay a dividend?
A

There are no upcoming dividends for Nabriva Therapeutics.

Q
When is Nabriva Therapeutics (NASDAQ:NBRV) reporting earnings?
A

Nabriva Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Nabriva Therapeutics (NBRV) going to split?
A

There is no upcoming split for Nabriva Therapeutics.

Q
What sector and industry does Nabriva Therapeutics (NBRV) operate in?
A

Nabriva Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.